AstraZeneca Tagrisso: Targeted lung cancer therapy in focus for US patients

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 1:08 PM ET. Details in the imprint.

Tagrisso is AstraZeneca’s best-selling targeted cancer medicine for certain patients with non-small cell lung cancer, and it has steadily expanded its role in US oncology practice over the past few years. The oral once-daily treatment is approved by the US Food and Drug Administration (FDA) for adults with metastatic or early-stage epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in several settings, including as adjuvant therapy after tumor resection. In 2024 the FDA approved Tagrisso in combination with chemotherapy for adult patients with locally advanced or metastatic EGFR-mutated NSCLC, broadening its use beyond monotherapy in the metastatic setting. For US patients and caregivers navigating lung cancer treatment options, Tagrisso has become one of the key targeted therapies to discuss with their oncology team.

What Tagrisso does and who it is for

Tagrisso (osimertinib) is a third-generation, irreversible EGFR tyrosine kinase inhibitor designed to selectively target tumors that carry specific EGFR mutations, including exon 19 deletions, L858R substitution, and the T790M resistance mutation. These genetic alterations drive cancer growth in a subset of NSCLC patients, and testing for EGFR mutations is now standard of care in advanced disease, which determines whether a drug like Tagrisso is appropriate. The medicine is taken as a tablet, with a commonly used dose of 80 mg once daily, which can simplify treatment compared with multi-drug infusion regimens in medical oncology clinics. For US patients, this oral format means the therapy is usually dispensed via specialty pharmacies with regular follow-up visits rather than frequent chemotherapy infusions.

In the metastatic setting, Tagrisso is approved as a first-line treatment for adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or L858R mutations, based on data showing improved progression-free and overall survival versus earlier EGFR inhibitors. It also has an indication for patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy, although the treatment landscape has shifted as more patients receive Tagrisso in the first-line setting. For early-stage disease, Tagrisso is approved as adjuvant treatment for adults with stage IB, II, or IIIA EGFR-mutated NSCLC after complete tumor resection, where it significantly reduced the risk of disease recurrence or death in the ADAURA trial. These labeled uses make Tagrisso relevant at multiple points in the patient journey, from early post-surgery treatment to advanced metastatic care.

Clinical outcomes reported in pivotal studies have been central to Tagrisso’s prominent position in treatment guidelines. In the ADAURA trial of adjuvant therapy, Tagrisso achieved a marked improvement in disease-free survival compared with placebo in patients with resected EGFR-mutated NSCLC, which supported its regulatory approvals and rapid adoption in practice. In the FLAURA trial assessing first-line metastatic therapy, Tagrisso led to longer progression-free survival and overall survival than earlier-generation EGFR inhibitors such as gefitinib and erlotinib, with a manageably similar safety profile. These results have been reflected in major US and international oncology guidelines, where Tagrisso is recommended for appropriate EGFR-mutated NSCLC populations. For patients and clinicians, the combination of survival benefit and once-daily dosing is a significant practical factor when comparing targeted options.

The safety profile of Tagrisso includes both common and serious side effects that require monitoring by oncology teams. Frequently reported adverse reactions include diarrhea, rash, dry skin, nail toxicity, and decreased appetite, which are typical for EGFR inhibitors and often manageable with supportive care. More serious risks, while less common, include interstitial lung disease (ILD)/pneumonitis, QT interval prolongation, and cardiomyopathy, which is why the prescribing information highlights the need for clinical vigilance and, where appropriate, cardiac and pulmonary monitoring. Patients with a history of lung disease or heart conditions may need closer follow-up while on therapy, and any new or worsening respiratory symptoms should be reported promptly to their doctor. For US consumers reading about Tagrisso, these safety considerations underline that it is a potent prescription-only cancer drug, not a general wellness product.

Pricing and access are critical aspects for US patients because Tagrisso is a branded oncology therapy with a high list price and no generic equivalent currently available. While AstraZeneca does not prominently list a US wholesale acquisition cost on the public product page, independent drug pricing resources and oncology pharmacies categorize Tagrisso among the higher-cost targeted cancer agents, typically reflecting monthly costs in the several-thousand-dollar range before insurance or discounts. Coverage in the United States depends on individual insurance plans, including commercial insurance, Medicare Part D, and other government programs, and patients may face coinsurance or prior authorization requirements. AstraZeneca operates patient support and copay assistance programs for eligible individuals through dedicated patient services, which may help reduce out-of-pocket costs for qualified US patients. For caregivers and patients, checking coverage early and discussing financial navigation with the oncology practice or specialty pharmacy is an important practical step when Tagrisso is prescribed.

Tagrisso’s role also needs to be seen in the context of AstraZeneca’s broader oncology portfolio and research pipeline. The company positions Tagrisso as one of its key oncology growth drivers, with significant global revenue contribution and ongoing clinical trials investigating combinations with other targeted agents, chemotherapy, and immunotherapies. Beyond NSCLC, AstraZeneca is researching Tagrisso-based regimens and related molecules across different stages and subtypes of lung cancer to extend the benefit of EGFR-targeted therapy to more patients. For US-based observers following the company, Tagrisso illustrates how a targeted therapy can move from a niche post-resistance indication into a backbone treatment across early and metastatic EGFR-mutated NSCLC.

From a corporate perspective, Tagrisso is one of AstraZeneca’s most important oncology brands and a central contributor to its global product sales. The medicine’s expanding indications in early-stage and metastatic disease, along with guideline endorsements, have supported its commercial performance in major markets, including the United States. Shares of AstraZeneca plc (GB0009895292, ticker AZN) traded at $200.69 on Nasdaq on April 20, 2026, according to recent market data.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.